Clinical trial

Expanded Access for IMMU-132

NCT04320693

StatusAPPROVED_FOR_MARKETING

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2021-08-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Triple-Negative Breast Carcinomaunresolved

Interventions

IMMU-132DRUG

Sponsors & collaborators

Gilead Scienceslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04320693 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.